Tezepelumab alters airway epithelial transcriptional responses and epithelial–smooth muscle signalling in uncontrolled asthma
BackgroundTezepelumab is a monoclonal antibody that targets thymic stromal lymphopoietin (TSLP). It reduces airway hyperresponsiveness, eosinophilia, mucus plugging, and asthma exacerbations, which are commonly caused by viral infections. Although clin…